Sanford C. Bernstein Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,070.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target cut by Sanford C. Bernstein from $1,110.00 to $1,070.00 in a report issued on Tuesday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the stock. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Royal Bank of Canada decreased their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Barclays decreased their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, Oppenheimer reduced their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. One analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $1,050.29.

Regeneron Pharmaceuticals Stock Up 2.0 %

Shares of NASDAQ REGN opened at $730.30 on Tuesday. Regeneron Pharmaceuticals has a 1 year low of $693.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a market cap of $80.25 billion, a PE ratio of 18.07, a price-to-earnings-growth ratio of 2.19 and a beta of 0.10. The company has a 50 day simple moving average of $760.25 and a 200 day simple moving average of $968.39.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the last quarter. Sachetta LLC lifted its position in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares in the last quarter. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter worth about $26,000. Fairfield Financial Advisors LTD purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $37,000. Finally, Ashton Thomas Private Wealth LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $39,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.